Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on May 21, 2004, covering events reported on May 24, 2004. The filing primarily addresses changes to the company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance.
Material Changes
- Board Appointment: Kenneth Kelley was named to the Board of Directors.
- Board Resignation: Edward Mercaldo resigned from the Board of Directors.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the personnel changes detailed in the accompanying press release (Exhibit 99.1).
Key Facts for Investor Verification
- Verify the background and qualifications of the new director, Kenneth Kelley.
- Confirm the reasons for Edward Mercaldo's resignation from the Board.
- Review the full text of the May 24, 2004 press release (Exhibit 99.1) for additional context on these governance changes.